Massachusetts General Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count).
Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.
Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.
Top-decile sponsor footprint
Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,032 total, page 37 of 41
Cognitive Effects of Treatment of Interictal Discharges
NCT00916149
Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease
NCT00438932
ARDSnet Protocol vs. Open Lung Approach in ARDS
NCT00431158
Comparison of Occupational Therapy and Home Exercises for Adults With Operatively Treated Distal Radius Fractures
NCT00438750
Normobaric Oxygen Therapy in Acute Ischemic Stroke Trial
NCT00414726
Dexmedetomidine for Postoperative Sedation in Patients Undergoing Repair of Thoracoabdominal Aortic Aneurysms
NCT00409344
Lifestyle Modification and Metformin Use in the Treatment of HIV
NCT00399360
Study of TNF-Antagonism in the Metabolic Syndrome (II)
NCT00413400
Dasatinib in Relapsed Chronic Lymphocytic Leukemia
NCT00438854
Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate
NCT00593138
Biochemical and Physiological Changes Associated With Differing Durations of Relaxation Response Training
NCT00636129
CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma
NCT00455897
A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)
NCT00321152
Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate
NCT00593112
Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
NCT00592293
Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma
NCT00592501
Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
NCT00392665
Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction
NCT01401699
Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia
NCT00833547
Effectiveness of Cognitive Behavioral Therapy for Treating Depression in People With Bipolar I Disorder
NCT00595387
Study of Medication Patch to Treat Children Ages 6-12 With ADHD
NCT00586157
Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home
NCT00505518
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
NCT00385853
Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
NCT00742079
Brain GABA Levels and Treatment Response in Major Depressive Disorder
NCT00464711
Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome
NCT00438321
Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
NCT00366457
Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking
NCT00218465
The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder
NCT00438971
Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy
NCT00916162
Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer
NCT00456144
Evaluation of Hand Assessments in Children With Severe Hand Burns
NCT00363675
Bevacizumab and Radiation Therapy for Sarcomas
NCT00356031
Clinical Trial Ceftriaxone in Subjects With ALS
NCT00349622
Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression
NCT00361374
Pain Responses in Patients on Long-Term Opioid Therapy for Chronic Pain
NCT00656942
Improving Adherence in Patients With Hypertension - A Novel Use of Communication Technology
NCT00277381
SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer
NCT00361244
Subclinical Atherosclerosis in HIV-infected Patients
NCT00455793
Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults
NCT00302393
A Comparison Study of the Efficacy and Tolerability of Depakote ER and Depakote DR
NCT00334347
Metabolic Effects of Switching Kaletra to Boosted Reyataz
NCT00413153
Calcium Supplementation for a Healthy Weight-Lite (CaSHeW Lite)
NCT00386672
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer
NCT00361231
Integrated Versus Standard Palliative Care in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT01038271
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
NCT00307736
Vitamin D Deficiency, Insulin Resistance and FGF-23
NCT00491322
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
NCT00513383
Comparison of Bovine Carotid Artery and Expanded Polytetrafluoroethylene (ePTFE) for Permanent Hemodialysis Access
NCT01021839
SU011248 in Advanced Hepatocellular Carcinoma
NCT00361309
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 226 |
| Phase 2 | 289 |
| Phase 3 | 58 |
| Phase 4 | 182 |
Therapeutic Areas
What is open in the Massachusetts General Hospital pipeline
336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).
Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).
Top condition: Depression (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.